David Medina, MD
Psychiatry · Orlando, FLNPI 1588805824
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 60.7% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $69,791, 4.8 times the $14,478 reported in 2019. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,062 payments — averaging $187.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$121K
- Acadia Pharmaceuticals Inc$18K
- Otsuka America Pharmaceutical, Inc.$17K
- Idorsia Pharmaceuticals US Inc$10K
- Alkermes, Inc.$10K
- AbbVie$5K
- plus $19K from 30 others
Across 563 payments — averaging $1607.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$404K
- Boehringer Ingelheim$249K
- AbbVie$99K
- Janssen Research & Development, LLC$86K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$15K
- Sumitomo Pharma America, Inc.$12K
- plus $40K from 7 others
What the payments were for
- Consulting fees$32,00116%
- Speaking & faculty fees$110,66256%
- Travel & lodging$22,91812%
- Food & beverage$33,16717%
- Education$5070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$116,403
- ARISTADA$29,634
- NUPLAZID$16,758
- REXULTI$15,646
- QUVIVIQ$9,599
- ARISTADA INITIO$7,292
- VRAYLAR$2,728
- AUSTEDO$1,439
- LYBALVI$1,012
- Auvelity$969
- CAPLYTA$833
- Austedo XR$812
- SPRAVATO$625
- UBRELVY$599
- COBENFY$491
- ABILIFY MAINTENA$462
- Fanapt$375
- ABILIFY ASIMTUFII$344
- VNS Therapy Symmetry Model 8103 Generator$230
- KISUNLA$125
How this compares
$199,254 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 38 | $468,296 |
| AustedoDeutetrabenazine | 50 | $304,723 |
| SpravatoEsketamine Hcl | 94 | $241,173 |
| NuplazidPimavanserin Tartrate | 37 | $180,132 |
| LybalviOlanzapine/Samidorphan Malate | 87 | $154,081 |
| RexultiBrexpiprazole | 116 | $149,292 |
| BelsomraSuvorexant | 185 | $88,051 |
| VraylarCariprazine Hcl | 47 | $63,781 |
| Abilify MaintenaAripiprazole | 21 | $56,727 |
| AuvelityDextromethorphan Hbr/Bupropion | 48 | $56,103 |
| FanaptIloperidone | 17 | $29,563 |
| Lurasidone Hcl | 96 | $21,677 |
| Quetiapine Fumarate | 881 | $21,183 |
| TrintellixVortioxetine Hydrobromide | 18 | $16,187 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $15,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $120,864 | $468,29638 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $4,391 | $304,72350 claims |
| Johnson & JohnsonSpravato, Risperdal Consta | $2,052 | $248,376105 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $17,201 | $206,019137 claims |
| Acadia Pharmaceuticals IncNuplazid | $17,881 | $180,13237 claims |
| Alkermes, Inc.Lybalvi | $9,643 | $154,08187 claims |
| MerckBelsomra | $66 | $88,051185 claims |
| AbbVieVraylar | $4,865 | $63,78147 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,886 | $56,10348 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $251 | $31,36754 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,122 | $29,56317 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $9,893 | $8,94819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Orlando
- Ramon MartinezOrlando$354K
- Carlos RuizOrlando$104K
- Morteza NadjafiOrlando$58K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.